Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study

Schizophrenia Research

Volumn 147, Issue 1, 2013, Pages 95-102

  Loebel, Antony ^a   Cucchiaro, Josephine ^a   Xu, Jane ^a   Sarma, Kaushik ^a   Pikalov, Andrei ^a   Kane, John M ^b,c  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Antipsychotic agents; Clinical trial; Drug therapy; Lurasidone; Quetiapine XR; Recurrence; Relapse; Schizophrenia

Indexed keywords

LURASIDONE; PLACEBO; QUETIAPINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITALIZATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REMISSION; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOINDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 84877148423     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.03.013     Document Type: Article

References (36)

1. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
2. Ascher-Svanum H., Zhu B., Faries D.E., Salkever D., Slade E.P., Peng X., Conley R.R. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010, 10(2). (Jan 7). 10.1186/1471-244X-10-2.
3. Axelrod B.N., Goldman R.S., Alphs L.D. Validation of the 16-item Negative Symptom Assessment. J. Psychiatr. Res. 1993, 27(3):253-258.
4. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
5. Bodén R., Sundström J., Lindström E., Lindström L. Association between symptomatic remission and functional outcome in first-episode schizophrenia. Schizophr. Res. 2009, 107(2-3):232-237.
6. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br. J. Psychiatry 2010, 196:116-121.
7. Cassidy C.M., Norman R., Manchanda R., Schmitz N., Malla A. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2years. Schizophr. Bull. 2010, 36:1001-1008.
8. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int. J. Clin. Pract. 2011, 65:189-210.
9. Citrome L., Cucchiaro J., Sarma K., Phillips D., Silva R., Tsuchiya S., Loebel A. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int. Clin. Psychopharmacol. 2012, 27:165-176.
10. Cox D. Regression models and life tables. J. Stat. Soc. 1972, 34:187-220.
11. Emsley R., Chiliza B., Asmal L., Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr. Opin. Psychiatry 2011, 24:114-121.
12. Guy W. EDCEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338) 1976, 534-537. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD.
13. Harvey P.D., Siu C., Loebel A. Cognitive performance in patients with schizophrenia treated with lurasidone: results from a 6-week core study and 6 month double-blind extension. Poster presented at the American Psychiatric Association Annual Meeting; May 7; Philadelphia, PA 2012.
14. Ishibashi T., Horisawa T., Tokuda K., Ishiyama T., Ogasa M., Tagashira R., Matsumoto K., Nishikawa H., Ueda Y., Toma S., Oki H., Tanno N., Saji I., Ito A., Ohno Y., Nakamura M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 2010, 334:171-181.
15. Johns M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991, 14:540-545.
16. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale Manual 1994, Multi-Health Systems, North Tonawanda, NY.
17. Kishimoto T., Agarwal V., Kishi T. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol. Psychiatry 2011, (Nov 29). 10.1038/mp.2011.143.
18. Latuda Prescribing Information Accessed on the web on May 12, 2012 at:. http://www.latuda.com/LatudaPrescribingInformation.pdf.
19. Leucht S., Barnes T.R., Kissling W., Engel R.R., Correll C., Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry 2003, 160:1209-1222.
20. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G., Davis J.M. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012, 379:2063-2071.
21. Liang K., Zeger S. Longitudinal data analysis for continuous and discrete responses for pre-post designs. Sankhya: Indian J. Stat. 2000, 62:134-148.
22. Loebel A., Cucchiaro J., Sarma K., Xu L., Hsu J., Kalali A.H., Pikalov A., Potkin S.G. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled, 6-week trial. Schizophr. Res. 2013, (Feb 13 [Epub ahead of print]).
23. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58:538-546.
24. Meltzer H.Y., Cucchiaro J., Silva R., Ogasa M., Phillips D., Xu J., Kalali A.H., Schweizer E., Pikalov A., Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am. J. Psychiatry 2011, 168:957-967.
25. Meyer J.M. Antipsychotics and metabolics in the post-CATIE era. Curr. Top. Behav. Neurosci. 2010, 4:23-42.
26. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
27. Nakamura M., Ogasa M., Guarino J., Phillips D., Severs J., Cucchiaro J., Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J. Clin. Psychiatry 2009, 70:829-836.
28. Peng X., Ascher-Svanum H., Faries D., Conley R.R., Schuh K.J. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon. Outcomes Res. 2011, 3:9-14.
29. Peuskens J., Trivedi J., Malyarov S., Brecher M., Svensson O., Miller F., Persson I., Meulien D. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry 2007, 4:34-50.
30. Peuskens J., Trivedi J.K., Brecher M., Miller F. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: posthoc analysis of data from a randomized withdrawal, placebo-controlled study. Int. Clin. Psychopharmacol. 2010, 25:183-187.
31. Piaggio G., Elbourne D.R., Altman D.G., Pocock S.J., Evans S.J., CONSORT Group Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006, 295:1152-1160.
32. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 2007, 64:1123-1131.
33. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970, 212:11-19.
34. Stahl S.M., Cucchiaro J., Simonelli D., Severs J., Loebel A., in press. Long-term safety and tolerability of lurasidone in patients with schizophrenia: results of a 6-month, open-label extension study. J. Clin. Psychiatry (ePublication ahead of print 3/13/13).
35. Weinmann S., Read J., Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr. Res. 2009, 113:1-11.
36. Zhornitsky S., Potvin S., Moteshafi H., Dubreucq S., Rompré P.P., Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int. Clin. Psychopharmacol. 2011, 26:183-189.